Original ArticleRole of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference
Cited by (0)
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Sources of funding: NIHR Biomedical Research Centre Oxford and the Oxford Cancer Imaging Centre.
This paper is based on the NET-Liver-Metastases Consensus Conference, 12–13 December 2012, London, endorsed by the European–African Hepato-Pancreato-Biliary Association (E-AHPBA), the European Neuroendocrine Tumor Society (ENETS), the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS), the European Society of Surgical Oncology (ESSO), the Great Britain and Ireland Hepato-Pancreato-Biliary Association (GBIHPBA), the International Hepato-Pancreato-Biliary Association (IHPBA) and the UK and Ireland Neuroendocrine Tumour Society (UKINETS).
Kennedy's institution received grant funding for clinical trial from Sirtex Medical. Bester received consultancy fees from Sirtex Medical. Salem, Parks, Ruszniewski and Sharma have no conflicts of interest.